| Identification | Back Directory | [Name]
tert-butyl N-(2-{7-[2-(4-cyano-2-fluorophenoxy)ethyl]-9-oxa-3,7-diazabicyclo[3.3.1]nonan-3-yl}ethyl)carbamate | [CAS]
872045-91-5 | [Synonyms]
AZD1305
UNII-CZO834LXQM
AZD-1305
(AZD1305)
AZD-1305, 10 mM in DMSO
tert-butyl N-(2-{7-[2-(4-cyano-2-fluorophenoxy)ethyl]-9-oxa-3,7-diazabicyclo[3.3.1]nonan-3-yl}ethyl)carbamate
Carbamic acid, N-[2-[7-[2-(4-cyano-2-fluorophenoxy)ethyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl]-, 1,1-dimethylethyl ester | [EINECS(EC#)]
642-445-9 | [Molecular Formula]
C22H31FN4O4 | [MOL File]
872045-91-5.mol | [Molecular Weight]
434.5 |
| Hazard Information | Back Directory | [Uses]
AZD-1305 is an antiarrhythmic agent and atrial selective sodium channel/potassium channel blocker, which can significantly prolongs action potential duration and reduces excitability, cause atrial selective ERP prolongation and acute termination of atrial fibrillation. AZD1305 can be used for atrial fibrillation research[1][2]. | [in vivo]
AZD-1305 (steady state plasma concentrations of 1.2 and 4.5 μM, i.v.drip) produces a greater prolongation of repolarization and ERP in canine atrium of Beagle dogs than in ventricle[1].
AZD-1305 (steady state plasma concentrations of 1.2 and 4.5 μM, i.v.drip) increases conduction time and depress excitability in atria versus ventricles of Beagle dogs [1].
AZD-1305 (steady state plasma concentrations of 1-3 μM, i.v.drip) terminates persistent AF and prevents induction of AF in an ACh-mediated model of AF in Beagle dogs [1].
| [References]
[1] Charles Antzelevitch, et al. AZD1305 Exerts Atrial Predominant Electrophysiological Actions and Is Effective in Suppressing Atrial Fibrillation and Preventing Its Reinduction in the Dog. [J] Cardiovasc Pharmacol. 2010, Volume 56，Number 1. DOI:10.1097/FJC.0b013e3181e0bc6b
[2] Serge Sicouri, et al. Electrophysiologic and antiarrhythmic effects of AZD1305 in canine pulmonary vein sleeves. THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 2010, Volume 334，Number 1. DOI:10.1124/jpet.110.166702
[3] Alexander Burashnikov, et al. AZD1305 exerts atrial predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its reinduction in the dog. J Cardiovasc Pharmacol. 2010 Jul;56(1):80-90. DOI:10.1097/FJC.0b013e3181e0bc6b |
|
|